Kornimate/medical-research-clean huggingface dataset:
antibacterial effect of new herbal paste used as an intracanal medication

Conditions: Infection Primary

Summary: studying the antibacterial effect of cosuts paste as an intracanal medication against enterococcus faecalis that present in necrotic primary teeth

the children were randomly divided into two groups (i, ii) group i (n=12): using costus-based paste as an intracanal medicament. group ii (n= 12): calcium hydroxide iodoform paste (metapex) as an intracanal medicament. procedure: access opening was started. then a swab was taken from the distal root canal with a dry paper point and transferred to a sterile test tube. the canals were filled with an intracanal medication according to the patient group. in group i, the canals was filled with a previously prepared costus-based paste for one week, and in group ii, the canals were filled with meta paste for one week. after 1 week, the paste was washed away from the canals then another swab was taken from the distal canal by a dry paper point as done before preoperatively. the 2 swabs were transferred within 2 hours to the lab for bacterial culture and detection of enterococcus faecalis count.

Eligibility criteria:
inclusion criteria: * patients with clinically and radiologically diagnosed infected primary teeth in their mandibular arch. * teeth should be deeply carious, with a history of spontaneous pain and carious exposures with necrotic pulp was also be selected * radiographic evidence of adequate alveolar bone support, and absence of internal or external resorption. * tooth must be restorable. exclusion criteria: * vital tooth * non restorable teeth

Keywords: infected primary molars, metapaste, herbal paste
electronic defaults to reduce opioid prescribing in emergency department and primary care settings

Conditions: Acute Pain

Summary: the goal of this research is to investigate the impact of changing opioid analgesic prescribing defaults on the quantity of opioids prescribed for acute non-cancer pain in adult primary care and emergency department settings. we will change prescribing defaults for select short-acting opioid analgesics including immediate release oxycodone and hydrocodone as well as codeine and tramadol, including their co-formulations with acetaminophen. in a cluster-randomized trial of matched pairs of montefiore medical center clinical sites, stratified by specialty and teaching status, we will evaluate the impact of this intervention on patient-level outcomes using 18 months of data (6 months pre-intervention and 12 months post-intervention).


Eligibility criteria:
clinical site inclusion criteria: * primary care clinic (internal medicine, family medicine, or urgent care) or emergency department within montefiore medical center patient inclusion criteria: * received a new opioid analgesic prescription, defined as no opioid analgesic prescription in the preceding 6 months patient exclusion criteria: * cancer diagnosis code within the past 1 year
hyperbaric oxygen treatment in patients with white matter hyperintensities

Conditions: Neurological Impairments; Leukoencephalopathies

Summary: the primary purpose of this study is to assess whether hyperbaric oxygen treatment improves neurological function in patients who exhibit white matter hyperintensities on mri examination. the secondary goal of this study is to determine if it is possible using mri to discern a difference in perfusion of central nervous system tissue in regions of white matter hyperintensities after hyperbaric oxygen administration as compared to hyperbaric air.

consecutively enrolled patients will be assigned to hyperbaric oxygen or hyperbaric air by random number. physicians supervising the hyperbaric treatments and the treating technicians, the evaluating neurologist, and the interpreter of the mris will be blinded regarding patient treatment status. all patients who receive placebo will be offered treatment with hyperbaric oxygen.

Eligibility criteria:
inclusion criteria: * over 50 years of age * white matter hyperintensities on mri of brain * two or more symptoms and/or neurological impairments e.g. gait disturbance, dysequilibrium, decline in cognitive function, upper motor neuron deficit, dysmetria, hyper-reflex or unilateral increase in muscle tone exclusion criteria: * contraindications to hyperbaric oxygen therapy e.g. pulmonary emphysema or bullae, claustrophobia, seizure disorder * inability of the patient to tolerate pressurization e.g. eustachian tube dysfunction * extreme cognitive impairment * major depression * other uncontrolled co-morbidities e.g. diabetes, hypertension, thyroid disorders, carotid artery stenosis (over 70%), renal or hepatic dysfunction * history of brain tumor, head trauma, electroshock therapy,brain irradiation or migraine headaches

Keywords: hyperbaric oxygen
how glargine insulin, oral diabetes medications and exenatide may improve blood sugar control and weight gain in type 2 diabetics

Conditions: Type 2 Diabetes

Summary: this study is designed to look at how using glargine insulin with oral diabetes medications and exenatide may improve control of blood sugar levels and weight gain in type 2 diabetics. the main study will last 32 weeks. however, all participants completing 32 weeks will be invited to continue for another 24 weeks taking the insulin and oral medication and exenatide treatment. this extension comparing insulin and oral medication with insulin and oral medication and exenatide will look at the long term weight loss/gain and blood sugar level control effects of this new drug regimen. there is also a sub-study in the clinical research center (crc), which requires two 38-hour inpatient stays during the main study. this study offers the opportunity to study 24-hour blood sugar and metabolic patterns quantitatively.


Eligibility criteria:
inclusion criteria: * male or female patients with type 2 diabetes * taking metformin at least 1000 mg daily plus a secretagogue, an alpha glucosidase inhibitor, a thiazolidinedione, or a single injection of any kind of insulin up to 0.4 units/kg daily for \> 3 months * age range 30 to 70 years * body mass index 25-45 kg/m2 * hba1c 7.0 to 10.0% (or 7.0 to 8.5% if the second antihyperglycemic agent is insulin) * less than 50% of randomized participants will have used insulin previously exclusion criteria: * use of more than two antihyperglycemic agents within the last 3 months * use of more than one daily injection of any kind of insulin in the last 3 months * positive anti-gad antibody (test required in screening) * fasting c-peptide \<0.5 ng/ml (test required in screening) * pregnancy (test required in screening if able to conceive) or lactation * excessive use of alcohol or evidence of other form of drug dependency * unwillingness or inability to grant informed consent * unwillingness or inability to perform self-monitoring of blood glucose * unwillingness or inability to inject insulin and/or inject exenatide * serum creatinine \>1.3 mg/dl in women or 1.4 in men * retinopathy which has required photocoagulation for treatment * major active systemic illness (e.g. neoplastic disorder, symptomatic ischemic heart disease, congestive heart failure) that might interfere with performing the study protocol * clinically significant gastrointestinal disorder including prior gastric or intestinal surgery for weight-control * ongoing use of any drug (e.g. narcotic analgesic, tricyclic antidepressant) that might alter gastric emptying * use prednisone or other systemic glucocorticoid drug in the last 3 months * use of any drug for weight-control (e.g. sibutramine, phentermine, orlistat) in the last 3 months * use of any unproven investigational drug within the last 3 months

Keywords: diabetes insulin byetta glucose blood sugar metformin a1c
evaluating modulation effects of burst stimulation patterns using seeg

Conditions: Epilepsy

Summary: the study aims to evaluate modulation effects of burst stimulation patterns via seeg.

our research group plans to conduct a study on patients with drug-resistant epilepsy who have seeg electrodes implanted. the study will evaluate and compare the modulation effect of single-pulse electrical stimulation, paired electrical stimulation, stepwise electrical stimulation, and burst electrical stimulation via direct electrical stimulation using seeg. the goal is to explore the focal and network modulation effect of distinct stimulation paradigms during the resting state and post-seizure state.

Eligibility criteria:
inclusion criteria: * drug-resistant focal epilepsy * justified seeg exploration in the context of presurgical assessment of epilepsy * subjects will be a part of the epilepsy-monitoring unit for long-term seeg recordings and analysis * written non-opposition to study participation exclusion criteria: * pregnant women (contraindication to seeg exploration) * psychiatric disorders * history of psychotic disorders * history of cranial trauma serious (according to the classification), previous or evolutionary other neurological pathology * subjects that experience surgical complications during the implant procedure will be excluded from the study

Keywords: burst stimulation patterns epilepsy seeg
savolitinib for treating gastric cancer and esophagogastric junction adenocarcinoma patients

Conditions: Gastric Cancer; Esophagogastric Junction Disorder

Summary: treating gastric cancer and esophagogastric junction adenocarcinoma patients with met gene amplifications with savolitinib

this is a single-arm, multi-cohort, multi-center, open-label, phase ii clinical study. the objective is to evaluate the efficacy and safety of savolitinib in the treatment of locally advanced or metastatic gastric cancer and esophagogastric junction adenocarcinoma patients with met gene amplifications. the study involves a screening period, a treatment period and a follow-up period. it is planned that about 30 study sites will enroll 75 patients

Eligibility criteria:
inclusion criteria: 1. fully aware this study and signed the informed consent form in voluntary manner, and willing and able to comply with the study procedure; 2. age ≥18 years; 3. histologically diagnosed locally advanced or metastatic gastric cancer and esophagogastric junction adenocarcinoma 4. met gene amplifications 5. cohort 1: having measurable lesions (in accordance with recist 1.1 criteria); cohort 2: having evaluable lesions 6. eastern cooperative oncology group (ecog) performance status 0 to 2 7. survival is expected to exceed 12 weeks; 8. adequate functionality in bone marrow, liver, kidney 9. able to take or swallow the drug orally. 10. female patients of childbearing potential must agree to use effective contraceptive methods from screening period to 30 days after discontinuation of the study drug,the male patients whose sexual partners are women of childbearing age must use condom during sexual intercourse during the study and within 6 months after discontinuation of study drug; exclusion criteria: 1. currently having other malignant tumors, or having other infiltrating malignant tumors in the past 5 years. stage i malignant tumor after radical treatment for at least 3 years, except those considered by investigators to have small possibility of recurrence. patients with radically treated carcinoma in situ (non-infiltrating) and skin cancer other than malignant melanoma can be enrolled; 2. having received antitumor therapy (including chemotherapy, hormone therapy, biotherapy, immunotherapy or traditional chinese medicine for antitumor indication) within 3 weeks prior to the start of study treatment, or having received treatment with small molecular tyrosine kinase inhibitors (e.g., egfr-tki) within 2 weeks prior to the start of study treatment;
the effectiveness and outcomes of epidural analgesia in patients undergoing open hepatectomy

Conditions: Epidural Analgesia; Patient Controlled Analgesia

Summary: this observational study is to compare the effectiveness and outcomes of epidural analgesia in patients undergoing open hepatectomy: a propensity score matching analysis. the main question is: what is the superior method of pain control in open hepatectomy: epidural analgesia or intravenous pca?

after approval of the study protocol from the institutional review board of chiangmai university (approval number: ane-2562-06771), the investigators performed a retrospective review of all patients who underwent an elective open liver resection in the specialized hepato-biliary center from january 2007 through december 2018. this retrospective inquiry comprised 612 patients. the data was systematically retrieved from electronic medical records. baseline characteristics including age, gender, body mass index (bmi), co-morbidity, american society of anesthesiologists (asa) classification, diagnosis, hepatitis profile, child-pugh classification, cirrhosis, the largest tumor size, previous liver resection, and pre-operative laboratory investigations were collected. the following intra-operative data were collected: type of liver resection, hilar resection, vascular reconstruction, intra-operative opioid consumption and type of fluid administration, estimated blood loss, packed red cell and blood product transfusion, and operation time. post-operative pain score and opioid consumption also be collected.

Eligibility criteria:
inclusion criteria: * all gender age above 18 years old * undergoing open liver resection surgery exclusion criteria: * no documentation of the numerical rating scale (nrs) * epidural failure

Keywords: liver resection propensity score matching
plasma lipid response to glucose drink

Conditions: Hyperlipidemias

Summary: during dietary fat absorption, the gut packages the majority of the fats into lipid particles that are secreted into blood circulation. the gut is also capable of storing a considerable amount of fats that can be released at a later time upon receiving certain stimulus signals. one of the signals is glucose ingestion. this protocol examines blood lipid responses to a glucose drink. participants drink a fatty formula and 5 hours later drink either a glucose solution or water (as control), in one of two randomized study visits. blood lipid levels are monitored throughout the study period.

participants are recruited after obtaining informed consent. they first have a high fat liquid formula. 5 hours later, they drink 50 grams of glucose in 50 ml of water in one visit and 50 ml of water in another. the 2 visits are randomized. blood samples are taken before and after they drink the high fat liquid formula, and continued until 3 hours after they drink glucose or water. lipid levels in the blood samples are measured in the lab.

Eligibility criteria:
inclusion criteria: * men and women, aged 18 to 60 years requiring endoscopy and duodenal biopsies for clinical indications, with no contraindications to the procedure, as judged by dr. bookman. * body mass index 20 to 27 kg/m2 exclusion criteria: * patients with active inflammatory bowel disease * patients with celiac disease, exocrine pancreatic insufficiency or small bowel malabsorption * patients with active bowel malignancy * patients with diabetes mellitus or known/ suspected motility disorders of the gut * patients with decompensated liver disease * patients on ezetemibe or bile acid sequestrants * unstable cardiac or respiratory disease * any changes to medication in the preceding month.
quality of life after vertebroplasty versus conservative treatment in patients with painful osteoporotic vertebral fractures

Conditions: Spinal Fracture; Osteoporosis; Back Pain

Summary: the purpose of this study is to determine whether percutaneous vertebroplasty is able to improve long-term quality of life in patients with pain secondary to osteoporotic vertebral fractures, compared to conventional medical treatment.

osteoporotic vertebral fractures are associated with pain and severe disability in a high percentage of patients. vertebroplasty has become the treatment of choice to alleviate pain in those patients who have not responded to medical treatment.although several case series and non-randomized studies have shown the effectiveness of vertebroplasty in alleviating pain secondary to osteoporotic vertebral fractures, the long-term effect of this treatment has not been compared to standard medical treatment in a randomized study. in our study we have analyzed the long-term effect of vertebroplasty in terms of quality of life in patients with painful osteoporotic vertebral fractures, randomizing them into two arms: percutaneous vertebroplasty or conventional medical treatment.

Eligibility criteria:
inclusion criteria: * painful (pain intensity of at least 4 on a scale from 0 to 10) osteoporotic vertebral fracture between levels t4 and l5 * fragility; i.e. fracture not in relation with significant trauma * recent fracture, pain beginning not earlier than 1 year before inclusion exclusion criteria: * no vertebral edema on stir mr images * uncorrectable bleeding diatheses * active infection * substantial retropulsion of bony fragments * non-osteoporotic fracture * concomitant neoplasm

Keywords: vertebroplasty disability evaluation outcome assessment pain measurement
nk cell therapy recurrent/refractory elderly aml

Conditions: AML; Recurrent; Refractory; Elderly

Summary: the aim of this investigation was to assess safety and efficacy of allogenic nk cells therapy for recurrent refractory elderly aml.


Eligibility criteria:
inclusion criteria: 1. the 2 or more than 2-cycles of standard regimen was used to treat elderly aml patients who did not achieve complete remission or relapse. 2. patients with age 60 years to 70 years. 3. kps greater than or equal to 60. 4. alt and ast are less than 3 times normal. 5. total bilirubin less than 1.5mg/dl(25.65umol/l). 6. serum creatinine less than 2.5mg/dl(221umol/l), or creatinine scavenging ability greater than or equal to 60 ml/min/1.73 m2. 7. left ventricular ejection fraction cardiac greater than or equal to 45%, echocardiography (echo) showed no pericardial effusion, electrocardiogram (ecg) is normal. 8. no pleural effusion in lungs 9. oxyhemoglobin saturation greater than or equal to 92% in normal environment. 10. kir mismatch between patient and umbilical cord blood. 11. volunteer to participate in the trial and sign the informed consent form. exclusion criteria: 1. malignant tumor patient. 2. patients who are accompanied by fungal, bacterial, viral, or other uncontrolled infections or require level 4 isolation( hbv-dna quantification and normal liver function in patients with hepatitis b infection are excluded). 3. patients with hiv, hcv positive. 4. patients with central nervous system diseases, including stroke, epilepsy, dementia, or autoimmune central nervous system disorders. 5. during the first 12 months of enrollment, patients with cardioangiography or stents, active angina pectoris or other clinically significant symptoms, or with cardiogenic asthma. 6. patients receiving anticoagulant therapy or with severe coagulation disorders. 7. according to the researcher's judgment, the drug treatment the patient is receiving will affect the safety and effectiveness of the study. 8. patients with allergies or history of allergies to biological agents used in this program. 9. systemic steroid used within 2 weeks before treatment (except for recent or present use of inhaled corticosteroids). 10. patients with other uncontrolled diseases, investigators think it is not suitable for the participants. 11. any circumstance that the investigator considers may increase the risk to the subject or interfere with the results of the study. 12. patients participate in other clinical studies.

Keywords: recurrent/refractory elderly aml nk cell
dose-ranging study of telintra® tablets + revlimid® in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (mds)

Conditions: Myelodysplastic Syndrome

Summary: this is an open label, multicenter phase 1 dose escalation study evaluating five doses of ezatiostat in combination with lenalidomide in patients with non-del(5q) low to intermediate 1 risk mds. the hi-e, hi-n, hi-p rates \[by international working group (iwg) 2006 criteria\] and safety of each treatment group will be evaluated to select the optimal dose of ezatiostat in combination with lenalidomide for future studies.


Eligibility criteria:
inclusion criteria: * histologic diagnosis of primary or de novo mds using who classification * non-del(5q) low or intermediate-1risk mds * ecog performance status of 0-1 * documented significant cytopenia for at least 2 months * must have discontinued growth factors (epo, g-csf, gm-csf) for at least 21 days prior to study entry * all study participants must be registered into the mandatory revassist® program and be willing and able to comply with the requirements of revassist® * females of childbearing potential should have two negative serum pregnancy tests with a sensitivity of at least 50 miu/ml. the first test should be performed within 10-14 days, and the second test within 24 hours of prescribing lenalidomide (prescriptions must be filled within seven days) exclusion criteria: * known hypersensitivity to telintra™ (intravenous or oral) * known prior therapy with or hypersensitivity to thalidomide or lenalidomide * prior allogenic bone marrow transplant for mds * history or prior malignancy * except for treated carcinoma of uterine cervix, basal cell or squamous cell skin cancer, or other cancers (e.g. breast, prostate) for which patient has been disease-free for at least 3 years. * mds evolving from: * a pre-existing myeloproliferative disorder * an autoimmune disease * secondary to prior treatment with radiation or chemotherapy * history of mds ipss score\>1.0 * pregnant or lactating women * leptomeningeal or leukemic meningitis * prior treatment with dna methyltransferase inhibitors (dmti) \[e.g., azacitadine, decitabine, etc.\]

Keywords: hematology mds myelodysplastic syndrome low risk mds patients with non-deletion(5q) non-deletion 5q non del(5q) revlimid lenalidomide telintra ezatiostat hydrochloride ezatiostat tlk199 glutathione glutathione analog glutathione transferase glutathione transferase inhibitor glutathione transferase p1-1 inhibitor gstp1-1 inhibitor apoptosis differentiation enzyme inhibitor